The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

GLP-1 drugs like Ozempic, Mounjaro, Zepbound, originally for adults, are now prescribed for adolescents with obesity, showing ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

The weight-loss drugs have grown in popularity, but are generally too expensive for most people to afford without insurance ...

A PRESENTER has candidly opened up on her “absolutely horrendous” experience while using Mounjaro. Danielle Mason, an ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The Columbia County Spring Fair is back in town, but this time with some policy changes amid disruptions last week.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...